Servier and Pieris Pharmaceuticals, a transatlantic biotech company, announced that the first patient has been dosed in the global phase 1/2 study for the treatment of solid tumors.
Pieris is advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications. Proprietary to Pieris, Anticalin® proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships.
The lead molecule of the alliance is a bispecific fusion protein comprising of 4-1BB-targeting Anticalin proteins and a PD-L1-targeting antibody. The global study will evaluate the safety, tolerability, potential optimal dosage, and potential anti-tumor activity of the molecule in patients with advanced solid tumors whose cancer progressed on standard-of-care treatment.
“The dosing of the first patient in this study marks a meaningful step to developing a potential future treatment for cancer patients with limited options.”
Servier and Pieris have been collaborating since 2017 on multiple strategic programs for the research and development of new therapies in immuno-oncology.